Transgender hormone therapy of the male-to-female MTF type, also known as transfeminine hormone therapy , is hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine or androgynous to feminine. Some intersex people also take this form of therapy, according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex , such as breasts and a feminine pattern of hair , fat , and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty , which may necessitate surgery and other treatments to reverse see below. The medications used for the MTF therapy include estrogens , antiandrogens , progestogens , and gonadotropin-releasing hormone modulators GnRH modulators. While the therapy cannot undo the effects of a person's first puberty , developing secondary sex characteristics associated with one's gender has been shown to relieve some or all of the distress and discomfort associated with gender dysphoria , and can help the person to "pass" or be seen as their gender.
Transgender hormone therapy (female-to-male)
Transgender Hormone Therapy | Star RX Pharmacy
The only unusual part of Ms. Miller is transgender, running in one of 17 states that allow high school athletes to compete as the gender they identify with, whether or not they have had medical intervention. Andraya Yearwood finished close behind Ms. Miller, and she is also transgender. It was nearly a quarter-second—an eternity in a race that lasts about seven seconds—before the rest of the field began to cross the line.
Trans women retain athletic edge after a year of hormone therapy, study finds
Sexual orientation is usually considered to be determined in early life and stable in the course of adulthood. In contrast, some transgender individuals report a change in sexual orientation. A common reason for this phenomenon is not known. The questionnaire focused on sexual orientation and recalled time points of changes in sexual orientation in the context of transition. Participants were further asked to provide a personal concept for a potential change in sexual orientation.
Andrew M. Kaunitz, MD reviewing Getahun D et al. Ann Intern Med Jul A large cohort study suggests that estrogen therapy increases risk for venous thromboembolism in male-to-female individuals. Many transgender individuals request medical treatment — estrogen for male-to-female MTF and testosterone for female-to-male FTM individuals — so that their physical appearance is aligned with their gender identity.